Recent research demonstrate that a new GLP-1 analogues, not only helps to lower blood glucose levels, but has the added benefit of reducing body mass index (BMI) and waist circumference.
Study shows that those patients with type 2 diabetes being treated with liraglutide (GLP-1 analogue), achieved significant reductions in both BMI and waist circumference, says Dr. Bernard Zinman, Director, Leadership Sinai Centre for Diabetes, Professor of Medicine, University of Toronto.
Since its approval by Health Canada in May of this year, Victoza(R) (liraglutide) is establishing its place among treatments to effectively manage diabetes. As the first GLP-1 analogue in Canada, Victoza(R) offers the added benefit of delayed gastric emptying and enhanced satiety after meals. To date, more than 2,600 Canadians living with diabetes have received treatment with Victoza(R)
Victoza(R) is indicated for once-daily administration for the treatment of adults with type 2 diabetes.
In addition, Victoza(R) has a low risk of hypoglycemia (dangerously low blood glucose levels), since it only works when the body needs it. Victoza(R) should not be used to treat type 1 diabetes mellitus or diabetic ketoacidosis. Use of Victoza(R) in combination with insulin has not been studied and is therefore not recommended.